Versatile use of Carmofur: A comprehensive review of its chemistry and pharmacology.

Abstract

Carmofur, 1-hexylcarbamoyl-5-fluorouracil (HCFU) is an antineoplastic drug, which has been in clinics in Japan since 1981 for the treatment of colorectal cancer. Subsequently, it was also introduced in China, Korea, and Finland. Besides colorectal cancer, it has also shown antitumor activity in other cancers such as breast, head and neck, pancreatic, gastrointestinal, and solid brain tumors. A prodrug of 5-fluorouracil (5-FU), carmofur has shown better gastrointestinal stability and superior antiproliferative activity compared to its active counterpart 5-FU. Recently, carmofur has gained attention as an acid ceramidase inhibitor and as a potential lead compound against several noncancerous diseases such as coronavirus disease 2019, Krabbe disease, acute lung injury, Parkinson's disease, dementia, childhood ependymoma etc. Carmofur has also been reported to have antifungal, and antimicrobial properties. Nevertheless, no comprehensive review is available on this drug. Herein, we summarized the chemistry, pharmacokinetics, and pharmacology of carmofur based on the literature published between January 1976 and March 2022 as identified from PubMed and Google Scholar search engines.

• Authors: Mohammad Mohiminul Islam, Shama P Mirza
• Journal: Drug development research (Drug Dev Res) Vol. 83 Issue 7 Pg. 1505-1518 (11 2022) ISSN: 1098-2299 [Electronic] United States
• PMID: 36031762 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 Wiley Periodicals LLC.

Chemical References

• Fluorouracil
• Antineoplastic Agents

Topics

• Humans
• Child
• COVID-19
• Fluorouracil (pharmacology)
• Antineoplastic Agents (pharmacology, therapeutic use)
• Brain Neoplasms (drug therapy)
• Colorectal Neoplasms (drug therapy)